Other biomarkers could provide additional information but may not be available in clinical practice, such as interleukin (IL)-6, tumor necrosis factor (TNF)-α, and IL-1β [3], identifying patients with a higher risk of plaque disruption or recurrence of short-term coronary events after acute coronary syndrome (ACS). Here, TNF is linked to acute coronary syndrome.